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Risk adapted high-dose and dose-dense therapies
modulate the impact of biological classification in
diffuse large B-cell lymphoma prognosis
Diffuse large B-cell lymphoma (DLBCL) is a highly het-
erogeneous disease entity.1 Young patients with high-inter-
mediate and high aa-IPI score seem to be good candidates
to receive alternative treatments to standard RCHOP-21
including EPOCH-R,2 R-ACVBP+HDT-ASCT3 and upfront
autologous stem cell transplantation.4 Other risk factors
can be used to identify patients for the use of more dose-
intense regimens including bulky disease, interim PET pos-
itivity and, importantly, molecular profiles.5-7 
The aim of our study was to evaluate whether high-dose
regimens in patients enrolled in clinical trials might modify
the prognostic impact of already recognized biological
markers in DLBCL (Cell of Origin (COO) classification,
MYC, BCL2 and BCL6 translocations, microRNA expres-
sion, MYC and BCL2 protein overexpression).
We analyzed a series of 156 patient samples. Patients
were enrolled in four clinical trials from GELTAMO,
PETHEMA and GOTEL and treated using  first-line dose-
dense or high-dose regimens (R-CHOP 14: 76 patient sam-
ples from 209 (36%) patients; dose-adjusted EPOCH-R: 42
patient samples from 81 patients included (52%); and
MegaCHOP-R plus stem cell transplantation based on
interim PET results: 38 patient samples from 71 patients
enrolled (53%)).8All samples received in the reference cen-
ter were included in the study and biological marker analy-
sis was only hampered by tissue limitations in specific
cases.
A summary of the major clinical characteristics of the
patients included in this study is shown in Table 1. The
study was approved by the Institutional Ethical
Committee of all participating institutions and by the
national regulatory agency according to Spanish law, and
complied with the Declaration of Helsinki. A retrospective
cohort of 240 cases of DLBCL treated with chemoim-
munotherapy was used for comparison.9
Centralized review of the histopathological diagnosis
was performed by 2 hematopathologists (SMM, MAP)
according to WHO classification.1 All cases were classified
according to the COO using the immunohistochemical
algorithms by Hans, Choi and Visco-Young.10-12
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Table 1. Clinical features of the series.
Number of patients 156 OS*, PFS** 76 OS*, PFS** 42 OS*, PFS** 38 OS, PFS Mega
pooled set RCHOP-14 EPOCH-R CHOP-R and BMT 
(76 patients) (42 patients) (38 patients)
IPI factors
Age *0.02, **0.003 *0.01,**0.0007 *ns, **ns *ns, ns**
≤60 years 90 (57%) 45 18 27
>60 years 63 (40%) 28 24 10
Stage *ns,**ns *ns,**ns *ns, **ns *ns, ns**
I-II 74 (47%) 31 42 1
III-IV 79 (50%) 42 0 36
LDH *ns,**ns *ns,**ns *ns,**ns *ns, ns**
low 49 (31%) 35 4 9
high 100 (64%) 36 38 26
Performance status *ns, **0.04 *0.001,**0.01 *ns,**ns *ns, ns**
Ambulatory (0-1) 107 (68%) 61 24 21
Not ambulatory (2-4) 43 (27%) 10 18 15
Extranodal site involvement *ns,**ns *ns,**ns *ns,**ns *ns, ns**
≤ 1 site 101 (64%) 54 30 17
> 1 site 49 (31%) 18 12 18
IPI score (number of IPI factors) *ns, **0.03 *ns,**ns *ns,**ns *ns, 0.03**
Low risk (0,1) 34 (22%) 30 3 1
Low – intermediate risk (2) 38 (24%) 22 5 11
High – intermediate risk (3) 56 (36%) 15 22 18
High risk (4,5) 25 (16%) 6 12 7
COO-CLASSIFICATION
GCB (according to Choi) 81/144 (56%) *ns,**ns 42 *ns,**ns 22 *ns,**ns 15 *ns,ns**
ABC 63/144 (44%) 25 18 18
GCB (according to Hans) 63/146 (43%) *ns,**ns 35 *ns,**ns 16 *ns,**ns 8 *ns, ns**
NON-GCB 83/146 (57%) 34 24 20
GCB (according to Visco-Young) 75/145 (52%) *ns,**ns 39 *ns,**ns 22 *ns,**ns 12 *ns, ns**
ABC 70/145 (48%) 29 18 21
CONCURRENT MYC-BCL2 IHC EXPRESSION
*ns,**ns *ns,**ns *ns,**ns *ns, ns**
DP* 31/117 (26%) 35 29 19
NON DP 86/117 (73%) 17 4 9
LDH: lactic dehydrogenase levels, IPI: International Prognostic Index; COO: cell of origin classification. GCB: germinal center B-cell type; ABC: activated B-cell type; 
NON-GCB: non-germinal center B-cell type; DP: double-positive for MYC and BCL2 immunohistochemical expression. NON-DP: non-double positive.
Immunohistochemical expression of BCL2 and C-MYC
was also scored. Interphase FISH analysis was performed
using Dual Color Break Apart DNA probes against BCL2,
BCL6 and C-MYC. microRNA expression signatures based
on RT-PCR were calculated and miRNA-based survival
models9 were applied for OS and PFS in this series of
patients. ROC analysis was performed to identify the high-
er sensitivity and specificity cut-off value for each survival
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Figure 1. (A, B) Overall survival (OS) and progression-free survival (PFS) Kaplan Meier estimates according to advanced age (>60 years
old). Patients under 60 years old had a probability of OS and PFS over 85%  in the median follow-up time. (C, D). IPI risk stratification into
Low, Low-intermediate, High-intermediate and High IPI was predictive for PFS (P < 0.05) but not OS. Patients with low IPI risk had an excel-
lent outcome with survival probabilities over 90% in the median follow-up time. However no differences were found among Low-interme-
diate, High-intermediate and High IPI risk. (C, D). OS and PFS Kaplan Meier estimates according to cell of origin classification: ABC type
DLBCL prognosis was significantly improved when compared with the R-CHOP 21 treated control cohort (P <0.005), while GCB type DLBCL
prognosis was not altered. Patients treated with high-dose and dose-dense therapies had an OS and PFS equivalent for both GCB and ABC
subtypes (81% vs. 84% for OS and 79% vs. 75% for PFS). (E, F). miRNA expression signatures were found of prognostic value for OS (P
log rank = 0.05) and PFS (P log rank 0.04). Cases with low miRNA score had a 90% ± 4 % PFS probability compared to 74% ± 4 % for
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function and cases were categorized into low miRNA
score and high miRNA score accordingly. Kaplan Meier
survival curves and multivariate analysis were made using
SPSS v11.
Overall survival and PFS at the median follow-up time
(46 months) were 83% (±3.3%) and 79% (±3.4%), respec-
tively. Median survival time for OS was 97.26 months
(±3.57) and median PFS were 88.04 months (±3.42).
Median age was 57 years old (range 17-80 years). No sig-
nificant differences were found in OS or PFS according to
the study protocol (Online Supplementary Figure S1).
Advanced age (>60 years) was predictive of poor OS and
PFS in the univariate analysis (P<0.05) for the pooled set of
patients and the RCHOP14 cases. Poor performance status
was predictive of poor PFS (P<0.05) (Table 1) for the
pooled set of cases and poor OS and PFS in the RCHOP14
cases (P=0.001 and P=0.01, respectively). IPI risk stratifica-
tion was predictive for PFS (P<0.05) but not OS (Table 1
and Figure 1). 
None of the IHC algorithms for COO subclassification
was predictive for OS or PFS in the whole series or after
treatment protocol stratification (Table 1). Interestingly,
ABC type DLBCL (according to Choi´s algorithm) progno-
sis was significantly improved in this series when com-
pared with the R-CHOP21 treated control cohort
(P<0.005), while there was no change in GCB type DLBCL
prognosis (Figure 1). 
MYC and BCL2 protein expression was quantified
according to previously published cut offs.9,13,14 Median
MYC protein expression was 30% and 54 of 116 (46%)
evaluable cases had an expression of 40% or over. Median
BCL2 protein expression was 50%. Sixty-seven of 124
(54%) evaluable cases had an expression of 50% or over
and 53 of 124 cases (42%) of 70% or over. Neither single
MYC nor BCL2 expression had an independent relation-
ship with OS or PFS. Furthermore, no significant statistical
differences were found according to concurrent expression
of MYC and BCL2 protein (so-called double positive
cases), irrespective of the cut off of positivity used (data not
shown).
Thirty-three of 117 (28%) cases had concurrent expres-
sion of MYC and BCL2 (>50%). Thirty-one of 117 cases
(26%) had co-expression of MYC and BCL2 (>70%). An
association between DP cases and high-stage (III-IV) dis-
ease (P<0.05)  and ABC-non-GCB molecular subgroup (χ2
<0.05 using V-Y algorithm) was found. By FISH, 6 (3.8%),
19 (12.1%) and 27 (17.2%) of the evaluable cases had
MYC, BCL2 and BCL6 translocations, respectively. Only 3
cases of double hit lymphoma were found (1 with MYC
and BCL2 translocations, 2 cases with MYC and BCL6
translocations). None of these genetic alterations was pre-
dictive for OS or PFS.
miRNA expression signatures were found of prognostic
value for OS (P=0.05; log rank) and PFS (P=0.04; log rank).
Cases with low miRNA score had a 90% ± 4% PFS prob-
ability compared to 74% ± 4% for cases with high miRNA
score (Figure 1). This effect was independent of advanced
age in the multivariate analysis for OS (RR for age of 2.96
and RR for miRNA score of 3.31; P=0.005) and PFS (RR for
age of 3.53 and RR for miRNA score of 3.76; P<0.001).
Patients aged under 60 years and those with a low miRNA
score had a probability of OS and PFS of over 85% and
90% in the median follow-up time, respectively. 
In summary, our results suggest that high-dose or dose-
dense therapies as a primary treatment for patients aged
under 60 years may overcome the negative impact of
ABC-type aggressive molecular subgroup and concurrent
MYC and BCL2 overexpression by IHC. These results are
in keeping with recent data that demonstrate a benefit for
high-intermediate and high risk patients with MYC posi-
tive DLBCL or BCLU treated with autologous stem cell
transplantation as consolidation therapy.4,15 
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